SCHEMBL5022709

SCHEMBL5022709

Cc1cc(N2CCCC2)c2ccc(NCc3cccnc3)cc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.50
NCF1 P14598 3/20 0.49
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 3/20 0.46
PABPC1 P11940 1/20 0.46
KDM4E B2RXH2 3/20 0.45
GAA P10253 1/20 0.45
HSD17B10 Q99714 2/20 0.43
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LTA4H P09960 1/20 0.42
GSK3B P49841 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025305 0.99 NCF1 (0.51) TERTNCF1ALDH1A1MEN1KMT2A
SCHEMBL5028716 0.87 NCF1 (0.50) NCF1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5024554 0.84 NCF1 (0.51) NCF1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5022553 0.84 NCF1 (0.51) TERTNCF1ALDH1A1MEN1KMT2A
SCHEMBL5025361 0.83 NCF1 (0.53) NCF1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5026871 0.82 NPC1 (0.52) NCF1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5024388 0.82 CTNNB1 (0.49) NCF1MEN1KMT2AGAACYP2C9
SCHEMBL5022744 0.82 MAPT (0.51) TERTNCF1ALDH1A1MEN1KMT2A
SCHEMBL5024595 0.80 RAB9A (0.54) NCF1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5028620 0.80 NCF1 (0.55) NCF1MEN1KMT2AHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474145-B1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-04-23 EP disclosed
EP-1474145-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-6696467-B2 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2004-02-24 US disclosed
WO-2003066055-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed
US-20030153553-A1 Quinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153553-A1 Quinoline derivatives NPY1R, NPY4R, GLP1R TERT 4619/4885NCF1 1858/4885ALDH1A1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.